JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
Stocks · News reference
8-K filing — BridgeBio Oncology Therapeutics, Inc. (BBOT)
Filed: 2026-06-22 AccNo: 0001193125-26-277513 Size: 148 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-expected earnings. Other big gainers: PRME, BZH, WULF, VRXA, BABA, ACDC, KC, PARR, SWMR, BBOT, KEX